1 completed, 1 recruiting. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Mark Pimentel, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Rifaximin With NAC in IBS-D rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo - IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant) | Phase 2 | Recruiting | Mark Pimentel, MD | 225 | 2026-02-04 | 2026-04-20 |
| Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome Neomycin, Placebo, Rifaximin - Constipation-predominant Irritable Bowel Syndrome | Not applicable | Completed | Mark Pimentel, MD | 37 | 2009-08-01 | 2015-08-10 |
Rifaximin (2) · Acetylcysteine (1) · Neomycin (1)
United States (2)